Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers

Experimental and Clinical Endocrinology and Diabetes

Volumn 110, Issue 8, 2002, Pages 416-419

  Von Mach, Marc Alexander ^a,b   Brinkmann, C ^a   Hansen, T ^a   Weilemann, L S ^a   Beyer, J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Crossover trial; Double blind; Insulin aspart; Insulin lispro; Randomized

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN ASPART; INSULIN LISPRO;

ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; GLUCOSE BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL DETECTION;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; RADIOIMMUNOASSAY;

EID: 12244255774     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36428     Document Type: Article

References (16)

1. Andersen L, Jørgensen PN, Jensen LB, Walsh D. A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence and pharmacokinetic studies. Clin Biochem 2000; 33: 627-633
2. Barnett AH, Owens DR. Insulin analogues. Lancet 1997; 349: 47-51
3. Bhaskar R, Chou MCY, Field JB. Time-action characteristics of regular and NPH insulin in insulin treated diabetics. J Clin Endocrinol Metab 1980; 50: 475-479
4. Bolli GB, Di Marchi RD, Park GD, Pramming S. Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151-1167
5. Hedman CA, Lindstrom T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care 24 (Letter) 2001; 1120-1121
6. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199-203
7. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: A randomized controlled trial. Diabet Med 2000; 17: 762-770
8. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin - A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402
9. B28) on meal-related plasma glucose excursions in type 1 diabetic subjects. Diabetes Care 1991; 14: 571-577
10. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468-477
11. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 asp-insulin): A fast-acting analog of human insulin: Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22: 1501-1506
12. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, Marfella R, Giugliano D. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: Role of fat and carbohydrate meals. J Am Coll Cardiol 2002; 39: 1145-1150
13. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-588
14. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926
15. Zinman B. The physiological replacement of insulin: An elusive goal. New Engl J Med 1989; 321: 367-370
16. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII. Results of a double-blind cross-over study. Diabetes 1997; 46: 440-443